Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cristina Ferraris

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The Breast Journal|October 10, 2013
Ex vivo MRI evaluation of breast tumors: a novel tool for verifying resection of nonpalpable only MRI detected lesionsRoberto Agresti, Giovanna Trecate, Cristina Ferraris, et al.
The British Journal of Surgery|March 5, 2025
Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trialRoberto Agresti, Marco Sandri, Giuseppe Capri, et al.
Annals of Surgical Oncology|November 18, 2025
Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional StudyGabriele Martelli, Francesco Barretta, Carlo Muzi, et al.
Cancers|April 3, 2021
Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer PatientsMarco Silvestri, Carolina Reduzzi, Giancarlo Feliciello, et al.
Critical Reviews in Oncology/Hematology|August 29, 2023
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunitiesEmma Zattarin, Ida Taglialatela, Riccardo Lobefaro, et al.
Breast (Edinburgh, Scotland)|February 4, 2014
Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-upRoberto Agresti, Flavio Crippa, Marco Sandri, et al.
International Journal of Cancer|August 24, 2023
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trialFrancesca Ligorio, Riccardo Lobefaro, Giovanni Fucà, et al.
Cancer|December 11, 2013
Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98)Roberto Agresti, Gabriele Martelli, Marco Sandri, et al.
Cancer Treatment Reviews|June 3, 2026
Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomesFlavia Jacobs, Alessio Polymeropoulos, Matteo De Monte, et al.
Breast (Edinburgh, Scotland)|November 21, 2025
Health-related quality of life and fear of recurrence after early breast cancer treatment: Results from a cross-sectional surveyPaola Mosconi, Secondo Folli, Rosalba Miceli, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Breast Journal|October 10, 2013
Ex vivo MRI evaluation of breast tumors: a novel tool for verifying resection of nonpalpable only MRI detected lesionsRoberto Agresti, Giovanna Trecate, Cristina Ferraris, et al.
The British Journal of Surgery|March 5, 2025
Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trialRoberto Agresti, Marco Sandri, Giuseppe Capri, et al.
Annals of Surgical Oncology|November 18, 2025
Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional StudyGabriele Martelli, Francesco Barretta, Carlo Muzi, et al.
Cancers|April 3, 2021
Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer PatientsMarco Silvestri, Carolina Reduzzi, Giancarlo Feliciello, et al.
Critical Reviews in Oncology/Hematology|August 29, 2023
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunitiesEmma Zattarin, Ida Taglialatela, Riccardo Lobefaro, et al.
Breast (Edinburgh, Scotland)|February 4, 2014
Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-upRoberto Agresti, Flavio Crippa, Marco Sandri, et al.
International Journal of Cancer|August 24, 2023
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trialFrancesca Ligorio, Riccardo Lobefaro, Giovanni Fucà, et al.
Cancer|December 11, 2013
Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98)Roberto Agresti, Gabriele Martelli, Marco Sandri, et al.
Cancer Treatment Reviews|June 3, 2026
Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomesFlavia Jacobs, Alessio Polymeropoulos, Matteo De Monte, et al.
Breast (Edinburgh, Scotland)|November 21, 2025
Health-related quality of life and fear of recurrence after early breast cancer treatment: Results from a cross-sectional surveyPaola Mosconi, Secondo Folli, Rosalba Miceli, et al.
Pageof 3